Oncology Briefings™: Application of Novel Therapies for the Treatment of Acute Myeloid Leukemia

Oncology Briefings™: Application of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML) is organized by Physicians' Education Resource, LLC (PER).

Release Date: October 31, 2019
Expiration Date: October 31, 2020

Accreditation:
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Activity Overview:
The treatment landscape of acute myeloid leukemia (AML) has expanded with the many recent clinical developments, and many more therapies are undergoing clinical trial investigation. Treatment paradigms are changing to reflect new clinical data. To optimize outcomes for patients with AML, healthcare practitioners need to access and effectively apply these data. This program is designed to address important competence gaps among practitioners who treat patients with hematologic malignancies by discussing current methods for accurate diagnosis, risk stratification, and multidisciplinary treatment after initial diagnosis and for later lines of treatment.

This Oncology Briefings™ program will help clinicians acquire the knowledge to meet these challenges through a series of audio interviews with Gail J. Roboz, MD, an expert in AML, who will discuss diagnostic and treatment guidelines for AML; important considerations throughout treatment, such as the level of patient fitness and the definition of minimal residual disease (or measurable residual disease; and the application of novel strategies to manage toxicities and comorbidities that can be particularly challenging in patients with AML.

Learning Objectives:
Upon successful completion of this educational activity, you should be better prepared to:
• Define best practices for risk stratification in patients with AML, methods of applying test results to patient care, and treatment monitoring strategies
• Contextualize the results of recent clinical trials with recently approved and emerging treatment options to inform the appropriate management of patients with AML
• Integrate optimized treatment approaches for AML, including treatment strategies indicated for elderly patients with AML
• Identify strategies for prompt identification and proactive management of treatment-related toxicities across the continuum of care in patients with AML